Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes
Authors' conclusion
We conclude that adjunctive tirzepatide treatment in OW/OB adults with T1D was associated with sustained improvements in CGM metrics over 12 months, without increased hypoglycemia risk in this real-world study. Proper long-term randomized control trials are needed to confirm our findings.
Study context
- Population
- Overweight or obese adults with T1D
- Participants
- 61 vs 54
- Comparison
- Adjunctive tirzepatide vs matched controls
- Tirzepatiden = 61
- Controlsn = 54reference
- Outcome
- TIR, between-group difference vs controls
- Follow-up
- 3, 6, 9 and 12 months
Methodological detailssingle-center, computer-matched controls (age, HbA1c, weight)
- Single-center
- Computer-matched controls (age, HbA1c, weight)
Main finding
As reported in the abstract
- Tirzepatide
- difference in time in range (TIR) at 3 months +4.6 %; P = 0.04
- Tirzepatide
- difference in TIR at 6 months +9.0 %; P < 0.001
- Tirzepatide
- difference in TIR at 9 months +6.9 %; P < 0.001
- Tirzepatide
- difference in TIR at 12 months +7.4 %; P < 0.001
- Time in tight range higher with tirzepatide at 6-12 months
- P ≤ 0.02
Observational data: associations, not effects.
Further findings
Composite CGM targets (TIR ≥70% and TBR <4%) · 12 months
P < 0.01
Safety
- TBR <70 mg/dL and TBR2 (<54 mg/dL) remained similar between groups throughout the study
- No severe hypoglycemia or DKA occurred in either group
Original publication
Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes. Diabetes Technol Ther. Published 10 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →